KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Net Cash Flow (2018 - 2025)

Moderna (MRNA) has disclosed Net Cash Flow for 8 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 416.96% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $666.0 million, a 166.67% increase, with the full-year FY2025 number at $666.0 million, up 166.67% from a year prior.
  • Net Cash Flow was $1.5 billion for Q4 2025 at Moderna, up from -$148.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $2.8 billion in Q1 2021 to a low of -$2.2 billion in Q2 2022.
  • A 5-year average of -$2.0 million and a median of $65.5 million in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 1705.77% in 2021, then tumbled 1450.93% in 2022.
  • Moderna's Net Cash Flow stood at $1.3 billion in 2021, then plummeted by 86.45% to $176.0 million in 2022, then plummeted by 114.2% to -$25.0 million in 2023, then skyrocketed by 1232.0% to $283.0 million in 2024, then surged by 416.96% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Net Cash Flow are $1.5 billion (Q4 2025), -$148.0 million (Q3 2025), and -$346.0 million (Q2 2025).